197 related articles for article (PubMed ID: 8860738)
21. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
22. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer?
Perachino M; Di Ciolo L; Barbetti V; Puppo P
Eur Urol; 1996; 29(3):366-9. PubMed ID: 8740025
[TBL] [Abstract][Full Text] [Related]
23. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
24. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.
Wolff JM; Ittel T; Boeckmann W; Reinike T; Habib FK; Jakse G
Eur Urol; 1996; 30(3):302-6. PubMed ID: 8931961
[TBL] [Abstract][Full Text] [Related]
25. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer.
Ataus S; Citçi A; Alici B; Onder AU; Sönmezoğlu K; Erözenci A; Solok V
Int Urol Nephrol; 1999; 31(4):481-9. PubMed ID: 10668943
[TBL] [Abstract][Full Text] [Related]
26. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract][Full Text] [Related]
27. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
28. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
29. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
[TBL] [Abstract][Full Text] [Related]
30. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
[TBL] [Abstract][Full Text] [Related]
31. Using prostate-specific antigen to eliminate the staging radionuclide bone scan.
Lee CT; Oesterling JE
Urol Clin North Am; 1997 May; 24(2):389-94. PubMed ID: 9126236
[TBL] [Abstract][Full Text] [Related]
32. [Is skeletal alkaline phosphatase a valid staging marker in detection of osteoblastic skeletal metastases of prostate carcinoma?].
Wirtz DC; Wolff JM; Ittel TH; Jakse G; Niethard FU
Z Orthop Ihre Grenzgeb; 1998; 136(3):255-9. PubMed ID: 9736988
[TBL] [Abstract][Full Text] [Related]
33. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
Haukaas S; Roervik J; Halvorsen OJ; Foelling M
Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
[TBL] [Abstract][Full Text] [Related]
34. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.
Ishizuka O; Tanabe T; Nakayama T; Kawakami M; Kinebuchi Y; Nishizawa O
Int J Urol; 2005 Aug; 12(8):728-32. PubMed ID: 16174046
[TBL] [Abstract][Full Text] [Related]
36. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis.
Tanaka N; Fujimoto K; Shinkai T; Nakai Y; Kuwada M; Anai S; Miyake M; Hirayama A; Hasegawa M; Hirao Y
Jpn J Clin Oncol; 2011 Oct; 41(10):1209-13. PubMed ID: 21862505
[TBL] [Abstract][Full Text] [Related]
37. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of alpha1-antichymotrypsin-PSA complex for predicting bone metastases of prostate cancer.
Kikuchi E; Nakashima J; Ishibashi M; Ohigashi T; Oya M; Nakagawa K; Miyajima A; Murai M
Urology; 2006 Aug; 68(2):371-5. PubMed ID: 16904455
[TBL] [Abstract][Full Text] [Related]
39. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Miller PD; Eardley I; Kirby RS
Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
[TBL] [Abstract][Full Text] [Related]
40. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
